Gilead to Acquire Arcellx in $7.8 Billion Deal

Gilead Sciences has announced its agreement to acquire U.S. biotechnology company Arcellx in a transaction valued at up to $7.8 billion. Bloomberg posted on X, highlighting the strategic move aimed at enhancing Gilead's portfolio in the biotech sector. The acquisition is expected to bolster Gilead's capabilities in developing innovative treatments and expand its presence in the market. This deal underscores Gilead's commitment to investing in promising biotech ventures to drive future growth. Further details on the transaction and its implications for both companies are anticipated as the acquisition progresses.